CALGARY, June 10 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that patient enrolment has started in a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous (IV) and intraperitoneal (IP) administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The National Cancer Institute (NCI), part of the National Institutes of Health, is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R). The Principal Investigator is Dr. David E. Cohn, Associate Professor, Division of Gynecologic Oncology at The Ohio State University College of Medicine in Columbus, Ohio.
"REOLYSIN(R) is an exciting agent to investigate in patients with ovarian cancer," said Dr. Cohn. "Targeting a specific alteration commonly present in these tumors will hopefully lead to efficacy with minimal toxicity."
"We are looking forward to working closely with the NCI to examine the effects of using REOLYSIN(R) with two concurrent methods of administration," said Dr. Brad Thompson, President and CEO of Oncolytics. "Our REOLYSIN(R) clinical program has now expanded to include ten Phase 1/2 or Phase 2 trials in the U.S. and the U.K. using REOLYSIN(R) as a monotherapy or in combination with radiation or chemotherapy."
In the Phase 1 portion of the trial, patients will receive a constant dose of IV REOLYSIN(R) on days 1-5 every 28 days, as well as an escalating dose of IP REOLYSIN(R) on days 1-2 every 28 days. In the Phase 2 portion of the study, patients will receive a constant dose of IV REOLYSIN(R) on days 1-5 every 28 days as well as the Maximum Tolerated Dose (MTD) of IP REOLYSIN(R) from the Phase 1 portion.
The primary objectives of the Phase 1 trial are to determine the safety
and tolerability of intravenous and intraperitoneal adminis
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved